Vice President, Reproductive Medicine
Ferring
About this role
The VP of Reproductive Medicine at Ferring Pharmaceuticals will lead the development and execution of the company's reproductive medicine strategy, building the therapeutic area and associated organization. Reporting to the Chief Medical Officer, the role focuses on driving innovation in clinical development and evidence generation to advance the global reproductive medicine portfolio.
Skills
Qualifications
About Ferring
ferringusa.comN/A
Recent company news
Business WireFerring Highlights New Real-World Research with ADSTILADRIN
Oct 28, 2025
BioSpaceFerring Unveils New Data with ADSTILADRIN® (nadofaragene firadenovec-vncg) at 112th Annual Meeting of the Japanese Urological Association
Apr 21, 2025
Fierce PharmaFerring opens doors to Finnish manufacturing hub as supply of its bladder cancer gene therapy continues to grow
Oct 3, 2024
Yahoo FinanceU.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)
Apr 24, 2025
Endpoints NewsADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence
Apr 21, 2025
About Ferring
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Leadership Team
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
Unlock Company Insights
View leadership team, funding history,
and employee contacts for Ferring.
Salary
$197k – $260k
per year
More jobs at Ferring
Similar Jobs
Manager- Business Development, Reproductive Medicine
Cryoport Systems
Vice President, Clinical Development and Trial Innovation
DELFI Diagnostics, Inc.
Associate Vice President Global Communications Immunology
Eli Lilly and Company
Vice President, Medial Affairs
Genetix Biotherapeutics
Associate Vice President – Global Communications Neuroscience
Eli Lilly and Company
Vice President, Late Stage Ophthalmology - DME
4D Molecular Therapeutics